Novel molecular imaging of atherosclerosis with Gallium-68-labeled Apolipoprotein A-I mimetic peptide and positron emission tomography

Circulation Journal

Volumn 77, Issue 6, 2013, Pages 1482-1489

  Kawachi, Emi ^a   Uehara, Yoshinari ^a   Hasegawa, Koki ^b   Yahiro, Eiji ^a,c   Ando, Setsuko ^c   Wada, Yasuhiro ^b   Yano, Tsuneo ^b   Nishikawa, Hiroaki ^a   Shiomi, Masashi ^d   Miura, Shin ichiro ^a   Watanabe, Yasuyoshi ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apo A I mimetic peptide; Atherosclerosis; High density lipoprotein; PET imaging; Plaque

Indexed keywords

APOLIPOPROTEIN A1; GALLIUM 68; HEPARIN; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA BIFURCATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CANNULATION; CONTROLLED STUDY; HEART INFARCTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; RABBIT; RADIOACTIVITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VASCULAR STENT;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETIC MATERIALS; GALLIUM ISOTOPES; HUMANS; PEPTIDES; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RABBITS; RADIOPHARMACEUTICALS;

EID: 84878243346     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0736     Document Type: Article

References (29)

1. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res 2012; 111: 231-244.
3. Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcifica-tion, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009; 2: 107-115.
4. 18F]-fuoro-deoxyglucose positron emission tomography. Circulation 2002; 105: 2708-2711.
5. Ohigashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, et al. Improved prognosis of Takayasu arteritis over the past decade: Comprehensive analysis of 106 patients. Circ J 2012; 76: 1004-1011.
6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. Am J Med 1977; 62: 707-714.
7. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: Role of cholesterol effux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-27.
8. Assmann G. Genes and dyslipoproteinaemias. Eur Heart J 1990; 11(Suppl H): 4-8.
9. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 2009; 338: b92.
10. Saku K, Zhang B, Noda K, Investigators PT. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ J 2011; 75: 1493-1505.
11. Soeda T, Uemura S, Okayama S, Kawakami R, Sugawara Y, Nakagawa H, et al. Intensive lipid-lowering therapy with rosuvas-tatin stabilizes lipid-rich coronary plaques: Evaluation using dual-source computed tomography. Circ J 2011; 75: 2621-2627.
12. Iwata A, Miura S, Zhang B, Imaizumi S, Uehara Y, Shiomi M, et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 2011; 218: 300-307.
13. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292-2300.
14. Uehara Y, Ando S, Oniki K, Abe S, Yahiro E, Tanigawa H, et al. FAMP, a powerful producer of pre-beta HDL via an ABCA1-medi-ated cholesterol effux pathway. Circulation (Meeting Abstr Suppl) 2010; 122: A12493.
15. Kamei N, Morishita M, Kanayama Y, Hasegawa K, Nishimura M, Hayashinaka E, et al. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography. J Control Release 2010; 146: 16-22.
16. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007; 48: 1741-1748.
17. Rosen JM, Butler SP, Meinken GE, Wang TS, Ramakrishnan R, Srivastava SC, et al. Indium-111-labeled LDL: A potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J Nucl Med 1990; 31: 343-350.
18. Worthley SG, Zhang ZY, Machac J, Helft G, Tang C, Liew GY, et al. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging 2009; 25: 251-257.
19. Ishino S, Mukai T, Kuge Y, Kume N, Ogawa M, Takai N, et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99 mTc-labeled anti-LOX-1 antibody: Potential agent for imaging of vulnerable plaque. J Nucl Med 2008; 49: 1677-1685.
20. Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: An autoradiographic study. Circulation 2001; 104: 203-208.
21. Saku K, Fujino M, Yamamoto K, Ying H, Tashiro N, Harada R, et al. Cardiac function of WHHL rabbit, an animal model of familial hy-percholesterolemia. Artery 1990; 17: 271-280.
22. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-1058.
23. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205.
24. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipo-protein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting effux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA 2007; 104: 15093-15098.
25. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: A multi-faceted biomolecule. Clin Chim Acta 2009; 410: 1-12.
26. Mineo C, Deguchi H, Griffn JH, Shaul PW. Endothelial and anti-thrombotic actions of HDL. Circ Res 2006; 98: 1352-1364.
27. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
28. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009; 50(Suppl): S195-S200.
29. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046.